Your browser doesn't support javascript.
loading
A Permission to Contact Platform Is an Efficient and Cost-Effective Enrollment Method for a Biobank to Create Study-Specific Research Cohorts.
Carvalho, Karlene; Gali, Brent; LeBlanc, Jodi; Matzke, Lise A; Watson, Peter H.
Afiliação
  • Carvalho K; Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Gali B; Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, Canada.
  • LeBlanc J; Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
  • Matzke LA; Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Watson PH; Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Biopreserv Biobank ; 19(4): 250-257, 2021 Aug.
Article em En | MEDLINE | ID: mdl-33464175
Background: The permission to contact (PTC) platform is a useful mechanism to increase patient engagement and enrollment into biobanks. It provides biobanks with the ability to select specific patient cohorts and to complete consent to facilitate access to biospecimens and data. In this study, we evaluated consenting costs for a biobank to compile a research cohort based on utilizing a PTC platform to obtain consent as compared with utilizing a prospective consenting approach. Methods: In this study, we utilized a PTC platform to conduct an initial selection of potential participants for two breast cancer cohorts and to provide a "referral" to the biobank to recontact these patients to provide consent to access clinical archival biospecimens and associated data. We evaluated the effort, costs, and cohorts compiled by this approach to compare this mechanism with the alternative: compiling the same type of cohorts based on a classic biobank enrollment approach. Results: After initial diagnosis and provision of a PTC up to 12 years before, recontact was possible in 84 of 90 (74%) and 77 of 107 (72%) breast cancer patients for preinvasive (ductal carcinoma in situ [DCIS]) and invasive (triple-negative subtype) cancers. Of those recontacted, consent was completed in 42 of 84 (55%) DCIS patients and 48 of 107 (45%) triple negative breast cancer (TNBC) patients. The total cost of using PTC to recontact patients to compile these two consented cohorts was CAD $26.34 and CAD $20.11 per patient consent, respectively. Conclusions: We have demonstrated the feasibility of utilizing a PTC platform to obtain informed consent from patients for a specific study through referrals provided several years after initial PTC was provided. Depending on the existing biobank operational model and the efficiency of its processes for enrollment and obtaining broad informed consent, the implementation of a PTC platform may be an efficient and cost-effective complementary method for a biobank to enroll patients to develop criteria-specific cohorts to support research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Bancos de Espécimes Biológicos / Consentimento Livre e Esclarecido Tipo de estudo: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Biopreserv Biobank Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Bancos de Espécimes Biológicos / Consentimento Livre e Esclarecido Tipo de estudo: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Biopreserv Biobank Ano de publicação: 2021 Tipo de documento: Article